← Leaderboards
Peter B Bitterman
University Of Minnesota Twin Cities
$13,879,552
Attributed
$14,273,212
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$20,754,299 · 11
By mechanism
R01$8,416,758 · 4
P50$7,241,497 · 2
P01$2,087,562 · 2
T32$1,656,799 · 1
R25$787,320 · 1
R21$564,363 · 1
Top collaborators
- Colin R Campbell5 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Russell V Luepker$29,051,624
- Colin R Campbell$5,492,770
- Daniel L Mueller$8,101,753
- Marc K. Jenkins$34,351,766
- Alexander Khoruts$3,964,061
Others in their field
Top investigators on “Fibroblasts”
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$57,068,242
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$37,747,421
- Joseph C Wu · Stanford University$36,488,088
- Kristin Ardlie · Genomics Collaborative, Inc.$34,108,405
- Gail V Anderson · La Biomed Res Inst/ Harbor Ucla Med Ctr$27,497,410
- Joseph E Robertson · Oregon Health & Science University$27,496,135
Research focus
FibroblastsBaseLungPropertyLung InjuryCellsTissuesHamman-Rich SyndromeGene ExpressionLesionProteinsTranslation InitiationTranslationsGrowth FactorPathway InteractionsMolecular TargetGenesPublicationsSignal TransductionLung DiseasesCell DivisionCell CycleLinkAffect
Grant awards (41)
Role of fibrotic extracellular matrix in generating the IPF Fibroblast$468,675
R01 · FY2018 · HL · contact PI
Role of fibrotic extracellular matrix in generating the IPF Fibroblast$468,675
R01 · FY2017 · HL · contact PI
Role of fibrotic extracellular matrix in generating the IPF Fibroblast$468,675
R01 · FY2016 · HL · contact PI
Summer Research at the University of Minnesota Medical School$157,464
R25 · FY2016 · HL
Role of fibrotic extracellular matrix in generating the IPF Fibroblast$468,675
R01 · FY2015 · HL · contact PI
Summer Research at the University of Minnesota Medical School$157,464
R25 · FY2015 · HL
Summer Research at the University of Minnesota Medical School$157,464
R25 · FY2014 · HL
Translational control of the fibroblast phenotype in IPF$454,956
P01 · FY2013 · HL · contact PI
Summer Research at the University of Minnesota Medical School$157,464
R25 · FY2013 · HL
Translational control of the fibroblast phenotype in IPF$477,894
P01 · FY2012 · HL · contact PI
Summer Research at the University of Minnesota Medical School$157,464
R25 · FY2012 · HL
Translational control of the fibroblast phenotype in IPF$477,893
P01 · FY2011 · HL · contact PI
Translational Control in IPF$419,662
R01 · FY2011 · HL · contact PI
Translational Control in IPF$433,366
R01 · FY2010 · HL · contact PI
Translational control of the fibroblast phenotype in IPF$334,698
P01 · FY2010 · HL · contact PI
Translational State Assay for Human Samples$186,863
R21 · FY2010 · RR · contact PI
Translational Control in IPF$445,667
R01 · FY2009 · HL · contact PI
Translational control of the fibroblast phenotype in IPF$342,121
P01 · FY2009 · HL · contact PI
Translational State Assay for Human Samples$188,750
R21 · FY2009 · RR · contact PI
Translational Control in IPF$458,034
R01 · FY2008 · HL · contact PI
Translational State Assay for Human Samples$188,750
R21 · FY2008 · RR · contact PI
Antifibrotic Drug Discovery in Acute Lung Injury$463,556
R01 · FY2007 · HL · contact PI
Molecular Targets for Drug Discovery in IPF$725,051
R01 · FY2006 · HL · contact PI
Antifibrotic Drug Discovery in Acute Lung Injury$469,318
R01 · FY2006 · HL · contact PI
Molecular Targets for Drug Discovery in IPF$742,500
R01 · FY2005 · HL
Antifibrotic Drug Discovery in Acute Lung Injury$451,823
R01 · FY2005 · HL
Molecular Targets for Drug Discovery in IPF$742,500
R01 · FY2004 · HL
Antifibrotic Drug Discovery in Acute Lung Injury$449,814
R01 · FY2004 · HL
SCOR IN ACUTE LUNG INJURY$1,431,761
P50 · FY2003 · HL
Molecular Targets for Drug Discovery in IPF$740,767
R01 · FY2003 · HL
SCOR IN ACUTE LUNG INJURY$1,728,873
P50 · FY2002 · HL
TRAINING IN LUNG SCIENCE$615,879
T32 · FY2002 · HL
TRANSLATIONAL CONTROL OF FIBROBLAST VIABILITY$245,455
P50 · FY2002 · HL
Translational repressors as therapy for OB$0
P01 · FY2002 · AI
SCOR IN ACUTE LUNG INJURY$1,693,052
P50 · FY2001 · HL
TRAINING IN LUNG SCIENCE$562,448
T32 · FY2001 · HL
TRANSLATIONAL CONTROL OF FIBROBLAST VIABILITY$245,455
P50 · FY2001 · HL
Translational repressors as therapy for OB$0
P01 · FY2001 · AI
SCOR IN ACUTE LUNG INJURY$1,627,401
P50 · FY2000 · HL
TRAINING IN LUNG SCIENCE$478,472
T32 · FY2000 · HL
TRANSLATIONAL CONTROL OF FIBROBLAST VIABILITY$269,500
P50 · FY2000 · HL